Videos

The consultant in the Department of Neurology at Mayo Clinic discussed the mounting number of unmet needs for patients with Parkinson disease.

Experts in the field of multiple sclerosis discuss patient selection for drugs based on disease activity.

Kristen Krysko, MD, summarizes the results of the phase III ORATORIO trial and discusses the rationale for using ocrelizumab for the treatment of progressive multiple sclerosis.  

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed the lack of studies on progressive MS compared to RRMS.

Variables that neurologists and other healthcare professionals need to consider when selecting an appropriate prescription therapy for migraine, and recommendations by a patient advocate on staying adherent to therapy and predicting attacks.

Limitations, in terms of safety and efficacy, of older conventional therapies used to treat migraine.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine provided plans of action to reduce racial and ethnic disparities in stroke.

The PhD candidate at the Barts MS Center in London discussed the upcoming Chariot MS study as well as further research she would like to conduct in personalized cladribine dosing.

Expert neurologist Lauren B. Krupp, MD provides insight into the use of diagnostic tools for pediatric multiple sclerosis such as MRI imaging, laboratory blood tests, and lumbar punctures.

Key opinion leaders in the management of MS comment on the current diagnostic criteria and discuss the importance of ruling out other common mimics in pediatric patients.

Alise Carlson, MD, a resident at Cleveland Clinic, provided insight on how raising awareness for genetic leukodystrophies may ultimately improve misdiagnosis rates.

The chief medical officer of Biohaven Pharmaceuticals discussed the recently initiated phase 2/3 clinical trial of zavegepant for the prevention of migraine.

The director and founder of the Sleep Centers of Middle Tennessee discussed his team’s efforts to further patient understanding of obstructive sleep apnea.

Episode 8 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and Robert M. Pascuzzi, MD, of Indiana University School of Medicine. [WATCH TIME: 4 minutes]

Expert neurologists discuss advancements in the management of narcolepsy including new drug formulations and provide take-home messages for how to improve diagnosis and treatment in the future.

A patient, Richard, discusses his positive experience with multiple sclerosis virtual visits during COVID-19.

Mary Ann Picone, MD, describes the incorporation of televisits for multiple sclerosis during COVID-19.

The consultant in the department of neurology at Mayo Clinic discussed Parkinson Disease Awareness Month and the benefits behind social initiatives that raise awareness.

The duo from Montefiore Medical Center discussed aspects of their recently published recommendations on neonatal seizure diagnosis that need further examining.

The professor of clinical neurology at University of Miami and MT2020+ chair, and president of Medtronic's Neurovascular Business discussed the effort to improve global accessibility of mechanical thrombectomy.

Neurology News Network for the week ending April 3, 2021.

Expert panelists provide recommendations for gene panel testing with genetic counseling for evaluation of patients with hereditary ATTR amyloidosis.

Diagnostic criteria commonly used to ensure an accurate diagnosis of hereditary ATTR amyloidosis is dissected.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed a number of presentations from ISC 2021.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed whether lenalidomide, a repurposed cancer drug, has promise as an Alzheimer disease DMT.

Experts in the field of multiple sclerosis compare the results of the EXPAND study to the results of the ASCEND study.

Robert Fox, MD, discusses the rationale for using siponimod for the treatment of progressive multiple sclerosis as well as the practical implications of the phase 3 EXPAND trial.

The duo from the National Institutes of Health discussed the advantages of the ultra-high resolution imaging technology in research.

The postdoctoral researcher at Columbia University discussed the long-term plans to gain a better understanding of MS diagnosis disclosure and how it can impact other qualities of life.

Neurologist Jessica Ailani, MD, explains when she feels it is most appropriate to treat migraine more aggressively with prescription drugs versus with lifestyle intervention.